Herantis Pharma receives orphan designation in USA for CDNF for treatment of...
(Source: Herantis Pharma Oyj) Herantis Pharma receives orphan designation in USA for CDNF for treatment of ALS Herantis Pharma Plc Company release 11 July 2016 at 9:00 am The United States Food and...
View ArticleCardio-Oncology Patients in the Cardiac Catheterization Laboratory (American...
(Source: American College of Cardiology Foundation) Patients with cancer have greatly improved survival with current chemotherapy and radiation therapies. This has resulted in many patients developing...
View ArticleInfinity Regains Worldwide Rights To Duvelisib Following Mutual Agreement...
(Source: Infinity Pharmaceuticals Inc) CAMBRIDGE, Mass., June 28, 2016 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that AbbVie Inc. has exercised its right to end its...
View ArticleVM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy...
(Source: ViroMed Co Ltd) First Pivotal Gene Therapy Trial to Target Underlying Cause of Diabetic Peripheral Neuropathy June 27, 2016 - Atlanta, GA- VM BioPharma, the United States division of ViroMed...
View ArticleCynapsus Therapeutics Enrolls Last Patient in Pivotal Phase 3 Efficacy Trial...
TORONTO, June 30, 2016 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc. (NASDAQ:CYNA) (TSX:CTH), a specialty central nervous system (CNS) pharmaceutical company developing and preparing to commercialize...
View ArticleAuris Medical Completes Enrollment of Phase 3 TACTT3 Trial with Keyzilen in...
Top-line results from TACTT3 trial expected in the fourth quarter Data to complement results from TACTT2 trial that are expected in August ZUG, Switzerland, June 28, 2016 (GLOBE NEWSWIRE) -- Auris...
View ArticleAlnylam Reports New Results from Investigational RNAi Therapeutic Programs...
(Source: Alnylam Pharmaceuticals Inc) 07.01.2016 - At 24 Months, Patisiran Shows a Mean 6.7 Point Decrease in Modified Neuropathy Impairment Score (mNIS+7), Comparing Favorably with an Expected Mean...
View ArticleMount Kilimanjaro trek looks for answers to heart and lung disease (Griffith...
(Source: Griffith University) Griffith Professor Norm Morris will join a medical research expedition to climb Mount Kilimanjaro in a bid to better understand pulmonary hypertension and heart failure by...
View ArticleEuropean Commission approves ONGENTYS® (opicapone) a novel treatment for...
(Source: ONO Pharmaceutical Co Ltd) 9d344446-190a-40ae-a15c-ef6fe487bcd9.pdf July 6, 2016 European Commission approves ONGENTYS® (opicapone) a novel treatment for Parkinson´s disease patients with...
View ArticleBrainstorm: New ALS Stem Cell Results Support Start of Pivotal Clinical Trial
More patients with amyotrophic lateral sclerosis (ALS) had a positive response to an injection of an experimental stem cell therapy developed by Brainstorm Cell Therapeutics (BCLI) compared to similar...
View ArticleAlnylam Reports New Results from Investigational RNAi Therapeutic Programs...
Alnylam Reports New Results from Investigational RNAi Therapeutic Programs for Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy (hATTR-PN) and Cardiomyopathy (hATTR-CM) – At 24 Months,...
View ArticleShire Announces Positive Topline ... (Shire plc)
(Source: Shire plc) June 29, 2016 Topline results revealed the study met its primary endpoints for both doses of SHP465 (12.5mg and 37.5mg) administered once daily, indicating superiority over placebo...
View ArticleTobira’s Cenicriviroc Reduces Inflammation and Fibrosis in Animal Models of...
Tobira’s Cenicriviroc Reduces Inflammation and Fibrosis in Animal Models of Chronic Liver and Kidney Disease Including NASH --Data Published in the Journal PLOS ONE-- Tobira Therapeutics, Inc. (NASDAQ:...
View ArticleABLYNX ANNOUNCES POSITIVE TOPLINE RESULTS FROM A PHASE IIb STUDY OF ITS...
ACR20, ACR50 and ACR70 scores of up to 81%, 49% and 24% respectively at week 12 Very encouraging efficacy data compared to tocilizumab with up to 41% of patients in clinical remission at week 12...
View ArticleEsperion Therapeutics Provides Clinical Development and Regulatory Update for...
(Source: Esperion Therapeutics Inc) June 28, 2016 On track to initiate global pivotal Phase 3 studies and CVOT in the fourth quarter Aligned with global regulatory authorities on a consistent...
View ArticleResults from Phase 2 Exploratory Clinical Study Support Continued Development...
(Source: Marinus Pharmaceuticals Inc) Anxiety and Hyperactivity Benefit shown in FXS Children Study Investigator to Participate in Conference Call and Webcast Today at 9:00 a.m. ET RADNOR, Pa., June...
View ArticleCytokinetics Announces Start of Phase 2 Clinical Trial of CK-2127107 in...
(Source: Cytokinetics Incorporated) SOUTH SAN FRANCISCO, Calif., June 30, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced the start of a randomized, double-blind,...
View ArticleClinical Predictors of Outcomes in HFpEF Patients (American College of...
(Source: American College of Cardiology Foundation) Study Questions: In patients with heart failure and preserved ejection fraction (HFpEF), what parameters predict clinical outcomes? Methods: This was...
View ArticleGlobal Blood Therapeutics Announces Initiation of Phase 2a Study of GBT440 in...
(Source: Global Blood Therapeutics Inc) SOUTH SAN FRANCISCO, Calif., June 29, 2016 /PRNewswire/ -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company developing novel...
View ArticleResults from Phase 2 Exploratory Clinical Study Support Continued Development...
Anxiety and Hyperactivity Benefit shown in FXS Children Study Investigator to Participate in Conference Call and Webcast Today at 9:00 a.m. ET RADNOR, Pa., June 28, 2016 (GLOBE NEWSWIRE) -- Marinus...
View Article